Protara Therapeutics, Inc.

NASDAQ:TARA

Biotechnology

Healthcare
$2.34 -1.27%

-$0.05 today

Market cap
$144.07M
Beta
1.45
P/E (TTM)
-2.7
EPS (TTM)
-$1.48
52W Low $2.77High $7.82

Volume 1.15M

Average 0.73M

TARA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Protara Therapeutics, Inc.NASDAQ: TARA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $19.54M rose 38.3% year over year, ahead of the +36.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +38.3% holds above the trailing-twelve-month pace of +36.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.54M+2.4% QoQ
Last fiscal yearDec 2025
$64.19M+30.6% YoY
LTMMar 2026
$69.96M+36.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.3%——
1 year+30.6%——
3-year CAGR-1.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
64.19M USD
Year-over-year change
+30.6%
4-year CAGR
+7.8%

Operating Expenses vs competitors

How TARA compares with its peers on the latest reported figures

  • TARA's LTM Mar 2026 operating expenses of $69.96M is the 6th highest of the 10 companies compared; the peer median is $87.45M.
  • Its year-over-year change of +36.0% is the 2nd highest of 9, against a peer median of -5.8%.
  • Over three fiscal years its annual growth of -1.4% compares with a peer median of -8.6%.
TARA Competitors Peer median
Operating Expenses for TARA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$144.88M -0.7%-22.5%419.2%
IVVDInvivyd, Inc.LTM Mar 2026$133.18M -26.8%-24.9%238.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$100.47M -31.6%-2.4%600.9%
CDXSCodexis, Inc.LTM Mar 2026$91.44M -11.0%-9.8%117.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$87.45M +22.4%+33.4%267.2%
TARAProtara Therapeutics, Inc.LTM Mar 2026$69.96M +36.0%-1.4%—
OABIOmniAb, Inc.LTM Mar 2026$68.18M -30.1%-7.4%235.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$39.45M +46.4%-12.9%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$33.36M ———
MDWDMediWound Ltd.LTM Mar 2026$30.87M +30.6%+11.1%213.2%
Peer median (excluding TARA) $87.45M-5.8%-8.6%238.4%

Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00341K0362K
Gross Profit00(341K)0(362K)
Gross Margin—————
Research & Development21.09M16.81M24.79M31.7M42.63M
Selling, General & Admin26.4M20.74M18.62M17.45M21.92M
Operating Expenses47.49M67.06M43.27M49.15M64.19M
Depreciation & Amortization117K248K341K332K362K
EBITDA(45.4M)(64.57M)(40.08M)(44.26M)(57.08M)
EBITDA Margin—————
Operating Income(47.49M)(67.06M)(43.61M)(49.15M)(64.55M)
Operating Margin—————
Interest Income237K1.11M2.73M4.14M6.33M
Interest Expense1.74M1.14M000
Other Income / Expenses237K1.11M3.19M4.56M7.11M
Income Before Tax(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Net Margin—————
EPS (Basic)(4.20)(5.86)(3.57)(2.17)(1.34)
EPS (Diluted)(4.20)(5.86)(3.57)(2.17)(1.34)
Weighted Avg Shares11.23M11.26M11.33M20.59M42.84M
Weighted Avg Shares (Diluted)11.23M11.26M11.33M20.59M42.84M

Protara Therapeutics, Inc.

NASDAQ:TARA

Intrinsic Alpha fair value

Locked

Current Price

$2.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.